{"name":"Applied Therapeutics","slug":"applied-therapeutics","ticker":"APLT","exchange":"NASDAQ","domain":"appliedtherapeutics.com","description":"Applied Therapeutics is a rare disease and metabolic disorder company focused on developing innovative treatments for patients with high unmet medical needs. The company's pipeline includes several promising candidates, including AT-007 and AT-001, which are being developed for the treatment of rare genetic disorders. With a strong focus on research and development, Applied Therapeutics is well-positioned to make a meaningful impact in the rare disease and metabolic disorder markets. The company's top drugs include AT-007 and AT-001, which are currently in various stages of development.","hq":"New York, NY","founded":0,"employees":"","ceo":"Shoshana Shendelman","sector":"Rare Disease / Metabolic","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$750M","metrics":{"revenue":455000,"revenueGrowth":-95.4,"grossMargin":0,"rdSpend":48744000,"netIncome":-105624000,"cash":86691000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"AT-007 patent cliff ($0.0B at risk)","drug":"AT-007","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"AT-001 patent cliff ($0.0B at risk)","drug":"AT-001","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AT-007","genericName":"AT-007","slug":"at-007","indication":"Diabetic peripheral neuropathy","status":"phase_3"}]}],"pipeline":[{"name":"AT-007","genericName":"AT-007","slug":"at-007","phase":"phase_3","mechanism":"AT-007 is a small molecule that inhibits aldose reductase, the first enzyme in the polyol pathway, to reduce sorbitol accumulation and prevent diabetic complications.","indications":["Diabetic peripheral neuropathy","Galactokinase deficiency"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Applied Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Applied Therapeutics reported its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and commercial operations.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Applied Therapeutics Announces Collaboration with the University of California, San Francisco","summary":"Applied Therapeutics announced a collaboration with the University of California, San Francisco to advance the development of its AT-007 program.","drugName":"","sentiment":"positive"},{"date":"2023-09-11","type":"regulatory","headline":"FDA Grants Fast Track Designation to AT-007 for the Treatment of Pyruvate Dehydrogenase Complex Deficiency","summary":"The FDA granted Fast Track designation to AT-007 for the treatment of pyruvate dehydrogenase complex deficiency, a rare genetic disorder.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1MQ3hiMXRDMEtZc2xUQXlOVUNuNFhzWExLNVlGX095YXpld3RTUUZtSEZXeEZaT0xRR2lQdzJoOVgwN1dzeHUzX3RQTGlUczFmd0xwNjFYQ0JRYkJoVGZuTmFkcl9HU1p4UVlKVmJn?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Applied Therapeutics (APLT) - Stock Titan","headline":"If You Invested $1,000 in Applied Therapeutics (APLT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNSVo2S2NrejZMeWpvQ0tGZnhDVmFmRlVfbVVQWUx2MkZ3NjdSOUtteUk5aDBFODB2X01Ja2hxYzByOVBIVTVXOGkxdVV4alRMZ0pRUFI3UlpvLU5ZMm9vZ1o2MnRrVmo5TnpsT3h2Z0x1SmJPc3pnbmRFMGFlMUE0ekh2RmpPLURZVUhyb0pueG90bkhQOTlZdmZOZUw1OG5icDNzQmQyYkU5a2V4dU5DQjlzZmhGSzFCdXZMSWNkaEUxUQ?oc=5","date":"2026-02-03","type":"pipeline","source":"Business Wire","summary":"Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics - Business Wire","headline":"Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics","sentiment":"neutral"},{"date":"2026-02-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWFVRNTZqbnMyN1hnZEhEaHFDR2Nvb3Ntd20xaUppVWJkdS1nVXE4VUxVRTFkSC1WcVdsbU5RQ0gwZjZZdjlodG5XZGVSOUVYVkVHWVNNTlJSeTRLNEdlU2tNRDBpUnQ5bkZzTWI1YVBsbWVERXlXR0VWTkhaNXFpZUxNeWxVNHA0cEZ1MHIxc2ZwOGtKTW1vQXRBVQ?oc=5","date":"2026-01-30","type":"pipeline","source":"Yahoo Finance","summary":"Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer - Yahoo Finance","headline":"Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPbHBGeDhOUlhiNjBDVnRyV2prTHhZVlNXTWQ4amYxOFl1azRFdmhmWUl1RUtqazlnVExnUlNtbmRtU0YzWnkySnhEdE9NeTFFR0dtdG9oN2l1VFlWRG9wM2hrM0wxNmxla3ExMDlBM29aMjVJUlN3YlZHMVljMXlGTFVNek94RjRlN3lZRmEzeXJTb3ZMZGVGRXd3RXpBaGN4ZTQtQ1piaEVuTGc3NUU0RTVDRndkX2VMU3c?oc=5","date":"2026-01-29","type":"pipeline","source":"Stock Titan","summary":"Applied Therapeutics warns: tender now or risk getting nothing - Stock Titan","headline":"Applied Therapeutics warns: tender now or risk getting nothing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOUTYxazZJdnBsVmExczFobVM5NWR4TGh0ZUtYUGl6dEQyb2xvRG42NnR1QnU3X3ZiWm5PcUtobkdRWGQ4aEZVUGIyRDRyX041U2duV3lzOGYtR3NTaXg3ZWowckR0RWltc3ZzMlBlSUVaM21jb1FZdUJXUC1qVHg5SWxHT21vTXExVzdOTUUwWUI0RGFOVVVSVE1HVjB1Yzk3MXFVRHNGS2dzYTFZSFE?oc=5","date":"2025-12-12","type":"pipeline","source":"Fierce Biotech","summary":"Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share - Fierce Biotech","headline":"Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNalRQM1JwcXB5dmpKbkJiTzUxQXV3V29pMjdEcHpBeEtCZlk3bnRnQm5CZnN0SU5iMHlpVV85X3JKUlR4b2lqcWJYTmsxYmQ4NUNrUWpveENRSUJUaW1hT2EzSGVNYnB1cS1rOUJwZnRqSFdBSVN6ZEIzZ1JkVDl0akd0WnptWERELThoaXZHUlB3UQ?oc=5","date":"2025-12-12","type":"deal","source":"The Pharma Letter","summary":"Cycle Pharma to acquire Applied Therapeutics - The Pharma Letter","headline":"Cycle Pharma to acquire Applied Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxOZE85ZEd1UmcweHhhVTltdmRGVHBVb084SFFWZEhaYXJwTFhNVHNhWHE4c1NCUWlMZjR0VW9WU2phQnZRYmF6Y2kxd296bnIzNF9yTE9mY3k5SkllRTRnSTdLeW4yVGtlakllNmdFWUh1VTBWc25OOVVmVm03TEJISkplbU5PZWhyUGxBTUVTU1R6X3BEenBIMDRqYVFoQzFGM2d5Q2JHQm4xNUh5WmhjY1hha2FRakJTWlVZZXhvcERmX1E?oc=5","date":"2025-12-12","type":"deal","source":"TechStock²","summary":"Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025) - TechStock²","headline":"Applied Therapeutics (APLT) Stock News Today: Cycle Deal Details, CVR Upside, and Analyst Outlook (Dec. 12, 2025) - Tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQcTlISk1GTlFoUE1zYUJ4X1ZjdHg5bEY4NjBDU1BSenpySGQxTkk4VWNRYktlS19pbl91ZHRlRWE0dXVabGZCUDFEMGFxck9MLUY2WlUtMmNkdTBETFNSb05mTEhXclBJMXpRNWJObGNzWVhFTGVUQ0l6STd2WTRLMHZHTWF5VVRvYndHZTA5OXI1b2xZUmxGUFJ3d3hIUms4azdZWlRsTGF2UkV4Y2ROdVB2bkNZQVRaMVhSY1g2aUVxZFU?oc=5","date":"2025-12-11","type":"deal","source":"globenewswire.com","summary":"Cycle Pharmaceuticals to Acquire Applied Therapeutics - globenewswire.com","headline":"Cycle Pharmaceuticals to Acquire Applied Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQVUI5N2I2ZkdwWU5aR3otVjg4U1Z5QWpSOVVxNVU4SUhndXRoNlpVZGdFRnhaMXpza0o1ZGM1QmVZMjlZVVVYQW9LYUpGVVQ2eE1KajBSckdSN21lNzRuZHVSaE0zSVZZTWQwTFVnRThBWjREX3o0X3M4elpZSDU5UzBvQWMxbEZNM2o2dE5fdVJqZ0VG?oc=5","date":"2025-12-11","type":"pipeline","source":"Seeking Alpha","summary":"Cycle Pharmaceuticals acquiring Applied Therapeutics - Seeking Alpha","headline":"Cycle Pharmaceuticals acquiring Applied Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQNnRqWmtFVmRRUXl6T0JienR0dzItbXlqd2RFSTdIMVBUdDNoZDYxNUQ2MkhPc1ZQZExxbzdEU1JSQ3luUnZnVFRlVmxDODc1aEd0UFRBbHBjYzV3YzJSTFAzX1ZKa2tiT29OeEJ1YkNFemhlSG8zVzYzb3ZONE5jMWxJS05LZ2MzRzdxalN4Zmd1cXRGQUhLZnNuQQ?oc=5","date":"2025-12-11","type":"earnings","source":"Stock Titan","summary":"Cycle to buy Applied Therapeutics (Nasdaq: APLT) in cash, CVR deal closing in Q1 2026 - Stock Titan","headline":"Cycle to buy Applied Therapeutics (Nasdaq: APLT) in cash, CVR deal closing in Q1 2026","sentiment":"neutral"}],"patents":[{"drugName":"AT-007","drugSlug":"generic-name-not-available","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"AT-001","drugSlug":"generic-name-not-available","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BioMarin Pharmaceutical Inc.","Pfizer Inc.","Sanofi"],"therapeuticFocus":["Rare Genetic Disorders","Metabolic Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":455000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":455000,"period":"2024-12-31"},{"value":9993000,"period":"2023-12-31"},{"value":9993000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":48744000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-105624000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":86691000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}